Fig. 1. Time schedule for the experimental design. CARD, normal rats supplemented with cardamonin; DM, untreated diabetic group; DM + GLIB, diabetic rats treated with glibenclamide; DM + CARD, diabetic rats treated with cardamonin; DM + GLIB + CARD, diabetic rats treated with both glibenclamide and cardamonin. ^#Represents the administration of STZ.

Korean J Physiol Pharmacol 2021;25:341-354 https://doi.org/10.4196/kjpp.2021.25.4.341

© Korean J Physiol Pharmacol